An Update on the Future of Wilson Disease Management

Overview

Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field.

Learning Objectives

After completing this educational activity, you should be able to:

  • Implement an individualized treatment strategy for the patient with WD, while watching for new options that could resolve unmet needs

Target Audience

Physicians and advanced practice providers who care for patients with WD, including primary care physicians, emergency medicine physicians, gastroenterologists, hepatologists and transplant hepatologists, and other health care providers on the treatment team.  

Abstract 

The recognition of Wilson disease (WD) has progressed over the last century from a neurologic disorder associated with liver disease to the understanding that WD is a rare autosomal recessive genetic disorder of copper metabolism. Due to WD’s myriad manifestations, its rarity, and broad range of symptoms, differential diagnosis may be challenging, leading to delays in treatment initiation. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field, including key clinical key clinical data and novel therapies in late-stage development, all of which ensure optimal management of WD in the coming years.

Activity summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Activity opens: 
11/21/2022
Activity expires: 
12/31/2023
Cost:
$0.00

Support Statement

Supported by an educational grant from Alexion Pharmaceuticals, Inc.

Learning Objective

After completing this educational activity, you should be able to:

  • Implement an individualized treatment strategy for the patient with WD, while watching for new options that could resolve unmet needs

Release, Review, and Expiration Dates

This CME activity was published in November 2022 and is eligible for AMA PRA Category 1 Credit™ through December 31, 2023. 

Statement of Need and Purpose

Wilson disease (WD) is a rare genetic metabolic disease that can be successfully treated if detected early. If untreated, WD is fatal. Treatment options for WD vary in administration and adverse effects. The rarity of WD, its multisystemic involvement, and its clinical heterogeneity make it difficult for a single practitioner to develop sufficient expertise to treat WD through clinical experience alone. Although guidelines are available, clinicians need education from experts on current and emerging treatment options for WD and on how to determine which treatment is most appropriate for which patient.

Unlabeled and Investigational Usage

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Review Process

The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.

The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter

© Copyright 2022 Physicians Postgraduate Press, Inc.

Faculty Affiliation

Robert S. Brown, Jr, MD, MPH
Weill Cornell Medicine
Center for Liver Disease
New York, NY

 


Financial Disclosure

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:

Individual Financial Disclosures

Dr. Brown has served as a consultant for Abbvie, Gilead, Intercept, Antios, and Ambys; received grant/research support from Abbvie, Gilead, Intercept and Mallinckrodt. 

Larry Culpepper, MD, MPH
Editor in Chief
Boston, MA 
Dr. Culpepper has been an advisor for AbbVie, Eisai, and Supernus; has been a stock shareholder of M-3 Information; and has received royalties from UpToDate. 

Michael R. Page, PharmD, RPh
Independent Medical Director/Medical Writer
Plainsboro, New Jersey
Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.

None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this activity.

Register for free on our site to participate in this and many other free CME courses.